Sucampo Pharmaceuticals Inc (SCMP) Issues FY14 Earnings Guidance
Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) updated its FY14 earnings guidance on Tuesday. The company provided EPS guidance of $0.08-0.13 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.18, Analyst Ratings.Net reports.
A number of analysts have recently weighed in on SCMP shares. Analysts at Roth Capital initiated coverage on shares of Sucampo Pharmaceuticals in a research note on Friday. They set a buy rating and a $9.00 price target on the stock. Analysts at MLV & Co
cut their price target on shares of Sucampo Pharmaceuticals from $14.00 to $11.00 in a research note on Friday, May 9th. They now have a buy rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $9.25.
Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) traded up 1.98% during mid-day trading on Tuesday, hitting $6.18. 32,036 shares of the company’s stock traded hands. Sucampo Pharmaceuticals Inc has a 52 week low of $5.40 and a 52 week high of $11.00. The stock’s 50-day moving average is $6.71 and its 200-day moving average is $7.42. The company has a market cap of $269.2 million and a price-to-earnings ratio of 24.94.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The company had revenue of $24.10 million for the quarter, compared to the consensus estimate of $24.06 million. The company’s revenue for the quarter was down 10.7% on a year-over-year basis. Analysts expect that Sucampo Pharmaceuticals Inc will post $0.18 EPS for the current fiscal year.
In other Sucampo Pharmaceuticals news, major shareholder Ryuji Ueno sold 16,155 shares of Sucampo Pharmaceuticals stock on the open market in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $6.26, for a total transaction of $101,130.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.